logo.png
Autonomix Enters into Definitive Agreement to License Intellectual Property for FDA-Cleared Ablation Technology from RF Innovations, Inc.
July 15, 2024 08:00 ET | Autonomix Medical, Inc.
RF Innovations’ Apex 6 Generator aligns with specifications required for Autonomix’s ablation system and facilitates ongoing development Transaction further reinforces Autonomix’s FDA...
logo.png
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Launch of CEO Corner Platform
July 11, 2024 09:00 ET | Autonomix Medical, Inc.
CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress Access the Autonomix CEO Corner Here! THE WOODLANDS, TX, July 11,...
logo.png
Autonomix Announces Positive Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial
June 18, 2024 08:00 ET | Autonomix Medical, Inc.
The first five patients successfully completed protocols with no immediate procedural-related complications or significant adverse events; Pain relief for responder group was experienced as quick as 1...
Autonomix Medical, Inc.
Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer
June 17, 2024 16:05 ET | Autonomix Medical, Inc.
Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX)...
logo.png
GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR
June 13, 2024 09:19 ET | GlucoTrack, Inc.
Completion of the novel epidural continuous glucose monitoring study confirms its potential for providing simplified disease management for patients with painful diabetic neuropathy Rutherford, NJ,...
SeaStar_SM_LogoCard.png
Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation
June 07, 2024 08:30 ET | SeaStar Medical Holding Corporation
DENVER, June 07, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar_SM_LogoCard.png
SeaStar Medical Announces 25-for-1 Reverse Stock Split
June 06, 2024 08:30 ET | SeaStar Medical Holding Corporation
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
logo.png
Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial
June 03, 2024 08:15 ET | Autonomix Medical, Inc.
Company plans to release topline results from “lead-in” patients (n=5) imminently THE WOODLANDS, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the...
logo.png
Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update
May 31, 2024 08:05 ET | Autonomix Medical, Inc.
Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued progress in first study ever to evaluate...
logo.png
Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer
May 23, 2024 09:15 ET | Autonomix Medical, Inc.
Results from the preclinical study demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass Lori Bisson, Chief Executive Officer...